LB Pharmaceuticals grants 75,000-share inducement option to new clinical operations SVP
The Nasdaq-listed biopharmaceutical company awarded Christopher Zergebel a 10-year stock option priced at $32.95 per share under the inducement grant exception in Nasdaq rules.